Nanotechnological carriers for cancer chemotherapy: the state of the art.

Cancer is a term used for a heterogeneous group of malignant diseases in which abnormal cells divide without control and are able to invade other tissues, resulting in metastasis. According to the last data of World Health Organization the incidence and mortality rates of cancer are high and tend to increase. Chemotherapy is usually used in cancer treatments, but due to the lack of specificity of drugs, is associated to various and damaging side effects that have a severe impact on patients quality of life. Nanotechnology is actually an important area of interest in science and technology, which has been extensively explored during the last decade, particularly in the development of carriers for cytotoxic drugs. These carriers include vesicular and particulate systems such as liposomes, niosomes, transfersomes, ethosomes, micelles, dendrimers, and polymeric, protein and lipid nanoparticles. Polymer-drug conjugates and antibody-drug conjugates have also been studied. The present review is an attempt to contemplate the studied nanocarriers in the field of anticancer drugs delivery, their advantages and disadvantages and future perspectives.

[1]  Andreas Wagner,et al.  Liposomes produced in a pilot scale: production, purification and efficiency aspects. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  Shuming Nie,et al.  Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery , 2006, Molecular Cancer Therapeutics.

[3]  Yi Yan Yang,et al.  Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. , 2014, Biomaterials.

[4]  Rahul P Gangwal,et al.  Oral delivery of anticancer drugs: challenges and opportunities. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[5]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .

[6]  A. Gabizon Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[7]  Ick Chan Kwon,et al.  Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Robert Gurny,et al.  Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  Ahmed O Elzoghby,et al.  Albumin-based nanoparticles as potential controlled release drug delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[11]  D. Fischer,et al.  Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[12]  John W. Park,et al.  Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. , 2008, Journal of pharmaceutical sciences.

[13]  V. Torchilin,et al.  Structure and design of polymeric surfactant-based drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[14]  T. Welte,et al.  Nanoparticle-based diagnosis and therapy. , 2006, Current drug targets.

[15]  Catarina Pinto Reis,et al.  Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. , 2006, Nanomedicine : nanotechnology, biology, and medicine.

[16]  Vladimir P Torchilin,et al.  PEG-based micelles as carriers of contrast agents for different imaging modalities. , 2002, Advanced drug delivery reviews.

[17]  John W. Park Liposome-based drug delivery in breast cancer treatment , 2002, Breast Cancer Research.

[18]  V. Torchilin,et al.  Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. , 1994, ImmunoMethods.

[19]  A. Ray,et al.  Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin. , 2013, International journal of pharmaceutics.

[20]  R. Müller,et al.  Investigation on the viscoelastic properties of lipid based colloidal drug carriers. , 2000, International journal of pharmaceutics.

[21]  Jiwon Kim,et al.  5-fluorouracil induced cardiotoxicity: review of the literature. , 2012, Cardiology journal.

[22]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[23]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[24]  K. K. Singh,et al.  Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  K. Gelmon,et al.  Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Schätzlein,et al.  Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. , 2002, Biochimica et biophysica acta.

[27]  D. Kerr,et al.  Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Shengfu Chen,et al.  Highly hemocompatible zwitterionic micelles stabilized by reversible cross-linkage for anti-cancer drug delivery. , 2014, Colloids and surfaces. B, Biointerfaces.

[29]  J. Iqbal,et al.  Development and in vivo evaluation of an oral drug delivery system for paclitaxel. , 2011, Biomaterials.

[30]  R. Wiwattanapatapee,et al.  Carboxymethylcellulose-tetrahydrocurcumin conjugates for colon-specific delivery of a novel anti-cancer agent, 4-amino tetrahydrocurcumin. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  P. Trail,et al.  Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. , 1997, Cancer research.

[32]  Jim Jiao Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. , 2008, Advanced drug delivery reviews.

[33]  A. Po,et al.  Oral vaccines: Design and delivery , 1991 .

[34]  R. Müller,et al.  Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. , 2004, International journal of pharmaceutics.

[35]  Hua Ai,et al.  Micellar carriers based on block copolymers of poly(ε-caprolactone) and poly(ethylene glycol) for doxorubicin delivery , 2004 .

[36]  S. Mitragotri,et al.  Endocytosis and Intracellular Distribution of PLGA Particles in Endothelial Cells: Effect of Particle Geometry. , 2010, Macromolecular rapid communications.

[37]  Xiguang Chen,et al.  Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy. , 2013, Carbohydrate polymers.

[38]  Jinming Gao,et al.  Theranostic nanomedicine for cancer. , 2008, Nanomedicine.

[39]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[40]  L. Brown Commercial challenges of protein drug delivery , 2005, Expert opinion on drug delivery.

[41]  E. Peira,et al.  Deformable liposomes for dermal administration of methotrexate. , 2004, International journal of pharmaceutics.

[42]  P. Kesharwani,et al.  Dendrimer toxicity: Let's meet the challenge. , 2010, International journal of pharmaceutics.

[43]  R. Nitschke,et al.  Quantum dots versus organic dyes as fluorescent labels , 2008, Nature Methods.

[44]  K. Ulbrich,et al.  Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[45]  Felix Kratz,et al.  Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[46]  D. Discher,et al.  Shape effects of filaments versus spherical particles in flow and drug delivery. , 2007, Nature nanotechnology.

[47]  Antje J Baeumner,et al.  Liposomes in analyses. , 2006, Talanta.

[48]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[49]  S. Eksborg,et al.  D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics , 2002, Hearing Research.

[50]  Yong Hu,et al.  Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. , 2009, Acta biochimica et biophysica Sinica.

[51]  P. Trail,et al.  Site‐directed delivery of anthracyclines for treatment of cancer , 1995 .

[52]  E. Eisenhauer,et al.  Current perspectives on camptothecins in cancer treatment. , 1996, British Journal of Cancer.

[53]  A. Estella-Hermoso de Mendoza,et al.  Efficacy of edelfosine lipid nanoparticles in breast cancer cells. , 2013, International journal of pharmaceutics.

[54]  V. Torchilin,et al.  Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  T. Minko,et al.  Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Hong Yuan,et al.  Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. , 2013, Colloids and surfaces. B, Biointerfaces.

[57]  K. Ulbrich,et al.  Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[58]  S. Simões,et al.  Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[59]  Yun-Xia Li,et al.  Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. , 2013, Cancer letters.

[60]  S. Chaudhari,et al.  Niosomes: novel sustained release nonionic stable vesicular systems--an overview. , 2012, Advances in colloid and interface science.

[61]  Y. Maitani,et al.  Entrapment of bleomycin in ultra-deformable liposomes , 2003 .

[62]  T. Allen,et al.  Liposomes , 2012, Drugs.

[63]  R. Duncan,et al.  Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.

[64]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[65]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[66]  R. Müller,et al.  Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. , 2002, Advanced drug delivery reviews.

[67]  Shonagh Walker,et al.  The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.

[68]  Yuliang Zhao,et al.  TPGS-stabilized NaYbF4:Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance. , 2015, Biomaterials.

[69]  B. W. Barry Is transdermal drug delivery research still important today? , 2001, Drug discovery today.

[70]  A. Lowman,et al.  Biodegradable nanoparticles for drug delivery and targeting , 2002 .

[71]  Lin Zhu,et al.  Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. , 2009, International journal of pharmaceutics.

[72]  V. Roy,et al.  Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer , 2011, Breast cancer : basic and clinical research.

[73]  D. Bissett,et al.  Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT) , 2004, British Journal of Cancer.

[74]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery , 1996 .

[75]  V. Torchilin,et al.  Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. , 1996, Biochimica et biophysica acta.

[76]  R. Müller,et al.  Cetyl palmitate-based NLC for topical delivery of Coenzyme Q(10) - development, physicochemical characterization and in vitro release studies. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[77]  J. Fréchet,et al.  Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. , 2004, Journal of the American Chemical Society.

[78]  Ze Lu,et al.  Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy , 2004, Clinical Cancer Research.

[79]  C. Pouton,et al.  Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[80]  G. V. Patil,et al.  Biopolymer albumin for diagnosis and in drug delivery , 2003 .

[81]  Forrest M Kievit,et al.  Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological Barriers , 2011, Advanced materials.

[82]  Y. Shimada,et al.  Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  H. von Briesen,et al.  Human serum albumin-polyethylenimine nanoparticles for gene delivery. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[84]  Maruyama,et al.  Possibility of active targeting to tumor tissues with liposomes. , 1999, Advanced drug delivery reviews.

[85]  F. Muggia,et al.  Liposomal encapsulated anthracyclines: new therapeutic horizons , 2001, Current oncology reports.

[86]  T. Xu,et al.  Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. , 2007, Current drug discovery technologies.

[87]  J. Schwarzbauer,et al.  Albumin-derived nanocarriers: substrates for enhanced cell adhesive ligand display and cell motility. , 2006, Biomaterials.

[88]  Samir Mitragotri,et al.  Red blood cell-mimicking synthetic biomaterial particles , 2009, Proceedings of the National Academy of Sciences.

[89]  P. Nayak,et al.  Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel , 2011 .

[90]  Hao Peng,et al.  The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. , 2013, Materials science & engineering. C, Materials for biological applications.

[91]  M. Dewhirst,et al.  Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. , 2000, Cancer research.

[92]  Kazunori Kataoka,et al.  Progress of drug-loaded polymeric micelles into clinical studies. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[93]  Antony D'Emanuele,et al.  Dendrimer-drug interactions. , 2005, Advanced drug delivery reviews.

[94]  D. Herrmann Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl lysophospholipid analogues. , 1985, Journal of the National Cancer Institute.

[95]  J. Kopeček,et al.  HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[96]  T. Minko Drug targeting to the colon with lectins and neoglycoconjugates. , 2004, Advanced drug delivery reviews.

[97]  Y. Obata,et al.  Novel ultra-deformable vesicles entrapped with bleomycin and enhanced to penetrate rat skin. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[98]  I. Zuhorn,et al.  Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. , 2004, The Biochemical journal.

[99]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[100]  Yoshiyuki Hattori,et al.  Ultra-deformable liposomes containing bleomycin: in vitro stability and toxicity on human cutaneous keratinocyte cell lines. , 2005, International journal of pharmaceutics.

[101]  D. Needham Materials Engineering of Lipid Bilayers for Drug Carrier Performance , 1999 .

[102]  Tongwen Xu,et al.  Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. , 2011, Chemical Society reviews.

[103]  R. Fram,et al.  XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. , 2009, Advanced drug delivery reviews.

[104]  Susan O'Brien,et al.  Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. , 2013, Clinical lymphoma, myeloma & leukemia.

[105]  M. Dewhirst,et al.  The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. , 2001, Advanced drug delivery reviews.

[106]  D. Paolino,et al.  Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[107]  J. Wanders,et al.  Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  Samir Mitragotri,et al.  Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. , 2010, Current pharmaceutical design.

[109]  Gustavo Helguera,et al.  The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. , 2006, Clinical immunology.

[110]  Y. Sakka,et al.  Single-phased luminescent mesoporous nanoparticles for simultaneous cell imaging and anticancer drug delivery. , 2011, Biomaterials.

[111]  Umesh Gupta,et al.  Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. , 2006, Biomacromolecules.

[112]  V. Torchilin,et al.  Immunoconjugates and long circulating systems: origins, current state of the art and future directions. , 2013, Advanced drug delivery reviews.

[113]  W. McGuire,et al.  Breast Cancer 4 , 1981, Springer US.

[114]  A. Huang,et al.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.

[115]  K. Kono,et al.  Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. , 2000, Bioconjugate chemistry.

[116]  F. Nicoletta,et al.  Doxorubicin loaded magneto-niosomes for targeted drug delivery. , 2013, Colloids and surfaces. B, Biointerfaces.

[117]  D. Kerr,et al.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. , 2009, International journal of oncology.

[118]  Jayanth Panyam,et al.  Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[119]  S. Zerp,et al.  Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. , 2001, International journal of radiation oncology, biology, physics.

[120]  J. Varshosaz,et al.  Synthesis of Pluronic® F127-poly (methyl vinyl ether-alt-maleic acid) copolymer and production of its micelles for doxorubicin delivery in breast cancer , 2014 .

[121]  C. Rhodes,et al.  Preparation and characterization of liposomes as therapeutic delivery systems: a review. , 1995, Pharmaceutica acta Helvetiae.

[122]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[123]  Xuesi Chen,et al.  Well-defined polymer-drug conjugate engineered with redox and pH-sensitive release mechanism for efficient delivery of paclitaxel. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[124]  J. Schellens,et al.  Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel , 2001, Anti-cancer drugs.

[125]  M. Khil,et al.  Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug. , 2009, Journal of biomedical materials research. Part A.

[126]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[127]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[128]  P. Štěpánek,et al.  Physicochemical aspects behind the size of biodegradable polymeric nanoparticles: A step forward , 2013 .

[129]  Vladimir P. Torchilin,et al.  Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[130]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[131]  R. Strickley Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.

[132]  Yoav D Livney,et al.  β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[133]  Jinwoo Cheon,et al.  Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. , 2008, Angewandte Chemie.

[134]  T. Xu,et al.  Dendrimers as drug carriers: applications in different routes of drug administration. , 2008, Journal of pharmaceutical sciences.

[135]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[136]  A. Aderem,et al.  Mechanisms of phagocytosis in macrophages. , 1999, Annual review of immunology.

[137]  Abraham H. Abouzeid,et al.  Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. , 2014, International journal of pharmaceutics.

[138]  S. Jain,et al.  A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.

[139]  Xing Guo,et al.  Redox-responsive polyanhydride micelles for cancer therapy. , 2014, Biomaterials.

[140]  K. Nugent,et al.  Cisplatin Nephrotoxicity: A Review , 2007, The American journal of the medical sciences.

[141]  Fabian Kiessling,et al.  Nanotheranostics and image-guided drug delivery: current concepts and future directions. , 2010, Molecular pharmaceutics.

[142]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  O. Boerman,et al.  Liposomes for scintigraphic detection of infection and inflammation. , 1999, Advanced drug delivery reviews.

[144]  Clemens Burda,et al.  The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. , 2012, Chemical Society reviews.

[145]  E. Cho,et al.  A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer , 2014, Cancer Chemotherapy and Pharmacology.

[146]  J. O’Shaughnessy Pegylated liposomal doxorubicin in the treatment of breast cancer. , 2003, Clinical breast cancer.

[147]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[148]  M. Dewhirst,et al.  Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. , 1996, International journal of radiation oncology, biology, physics.

[149]  David S. Horne,et al.  Casein micelle structure : Models and muddles , 2006 .

[150]  F. Rinaldi,et al.  Niosomes from 80s to present: the state of the art. , 2014, Advances in colloid and interface science.

[151]  M. Muhammed,et al.  Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging. , 2014, Biomaterials.

[152]  M. Singh,et al.  Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[153]  Hong Wu,et al.  Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma. , 2010, Biomacromolecules.

[154]  Robert Gurny,et al.  Drug-loaded nanoparticles : preparation methods and drug targeting issues , 1993 .

[155]  Youqing Shen,et al.  Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers , 2010 .

[156]  Kai Yang,et al.  Nano-graphene in biomedicine: theranostic applications. , 2013, Chemical Society reviews.

[157]  D. Tomalia Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry , 2005 .

[158]  R Blumenthal,et al.  Design of liposomes for enhanced local release of drugs by hyperthermia. , 1978, Science.

[159]  Y. Nakanishi,et al.  Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts , 2004, Cancer science.

[160]  Kinam Park Albumin: a versatile carrier for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[161]  María J. Vicent,et al.  Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. , 2009, Advanced drug delivery reviews.

[162]  J. Schnitzer gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. , 1992, The American journal of physiology.

[163]  K. Beningo,et al.  Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. , 2002, Journal of cell science.

[164]  Felix Kratz,et al.  Impact of albumin on drug delivery--new applications on the horizon. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[165]  A. Schätzlein,et al.  Dendrimers in gene delivery. , 2005, Advanced drug delivery reviews.

[166]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[167]  S. Mitragotri,et al.  Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. , 2011, Advanced drug delivery reviews.

[168]  R. Schubert,et al.  Effect of beta-sitosterol on the characteristics of vesicular gels containing chlorhexidine. , 2004, International journal of pharmaceutics.

[169]  Thomas L Andresen,et al.  Liposome imaging agents in personalized medicine. , 2012, Advanced drug delivery reviews.

[170]  N. Desai Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC , 2007 .

[171]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[172]  B. Kinsey,et al.  Targeted delivery of expression plasmids to the lung via macroaggregated polyethylenimine-albumin conjugates. , 2003, Methods in molecular medicine.

[173]  You Han Bae,et al.  Drug targeting and tumor heterogeneity. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[174]  George R. Newkome,et al.  MICELLES. PART 1. CASCADE MOLECULES: A NEW APPROACH TO MICELLES. A (27)-ARBOROL , 1985 .

[175]  G. P. Kumar,et al.  Nonionic surfactant vesicular systems for effective drug delivery—an overview , 2011 .

[176]  Y. Barenholz Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[177]  I. Uchegbu,et al.  Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry , 1995 .

[178]  Y. M. Lee,et al.  Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. , 2001, Biomaterials.

[179]  G M Tozer,et al.  Modification of tumor blood flow: current status and future directions. , 1998, Seminars in radiation oncology.

[180]  Tianwei Tan,et al.  Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo. , 2007, International journal of biological macromolecules.

[181]  K. Ulbrich,et al.  Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice , 2006, Cancer Immunology, Immunotherapy.

[182]  M. Michaelis,et al.  Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. , 2007, International journal of pharmaceutics.

[183]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[184]  J. Kopeček,et al.  Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[185]  Adrian C. Williams,et al.  Skin delivery of 5‐fluorouracil from ultradeformable and standard liposomes in‐vitro , 2001, The Journal of pharmacy and pharmacology.

[186]  Adrian C. Williams,et al.  Skin Delivery of Oestradiol from Deformable and Traditiona Liposomes: Mechanistic Studies , 1999, The Journal of pharmacy and pharmacology.

[187]  M. Otagiri,et al.  Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin , 2002, Pharmaceutical Research.

[188]  A. Gabizon Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[189]  A. Tolcher,et al.  A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  Y. Barenholz,et al.  Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids. , 1995, Biochimica et biophysica acta.

[192]  F. Chang,et al.  Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[193]  Y. Assaraf,et al.  Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[194]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[195]  A. R. Kulkarni,et al.  Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[196]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[197]  Z. Yi,et al.  Poly(gamma,L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. , 2006, Biomaterials.

[198]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[199]  W. Gradishar,et al.  Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  J. Verweij,et al.  Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors , 2005, Clinical Cancer Research.

[201]  P. Low,et al.  Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.

[202]  Vladimir P Torchilin,et al.  Lipid-core micelles for targeted drug delivery. , 2005, Current drug delivery.

[203]  R. Tekade,et al.  Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: A comparative assessment. , 2012, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[204]  T. Saba Physiology and physiopathology of the reticuloendothelial system. , 1970, Archives of internal medicine.

[205]  R. Andreesen,et al.  Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. , 1979, Cancer research.

[206]  G. Cevc Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. , 1996, Critical reviews in therapeutic drug carrier systems.

[207]  M. Amiji,et al.  Poly(ethylene oxide)-modified poly(ɛ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer , 2005 .

[208]  J. Pardeike,et al.  Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. , 2009, International journal of pharmaceutics.

[209]  J. Brender,et al.  Solid-state NMR reveals the hydrophobic-core location of poly(amidoamine) dendrimers in biomembranes. , 2010, Journal of the American Chemical Society.

[210]  J. Bouwstra,et al.  Vesicles as a tool for transdermal and dermal delivery. , 2005, Drug discovery today. Technologies.

[211]  Karsten Mäder,et al.  Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[212]  G. Salzano,et al.  Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer. , 2014, Cancer letters.

[213]  A. Malik,et al.  Gp60 Activation Mediates Albumin Transcytosis in Endothelial Cells by Tyrosine Kinase-dependent Pathway* , 1997, The Journal of Biological Chemistry.

[214]  Y. Shechter,et al.  Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin. , 2005, Bioconjugate chemistry.

[215]  Y. D. Livney,et al.  Milk proteins as vehicles for bioactives , 2010 .

[216]  Alexander V Kabanov,et al.  Nanocarriers for delivery of platinum anticancer drugs. , 2013, Advanced drug delivery reviews.

[217]  M. R. Mozafari,et al.  Liposomes: an overview of manufacturing techniques. , 2005, Cellular & molecular biology letters.

[218]  A. Malik,et al.  Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. , 2009, ACS nano.

[219]  Shashank K Singh,et al.  Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. , 2014, International journal of pharmaceutics.

[220]  Y. Assaraf,et al.  Beta-casein Nanoparticles as an Oral Delivery System for Chemotherapeutic Drugs: Impact of Drug Structure and Properties on Co-assembly , 2010, Pharmaceutical Research.

[221]  E. Gamelin,et al.  Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU , 1996, Cancer.

[222]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[223]  V. Torchilin,et al.  Multifunctionality of lipid-core micelles for drug delivery and tumour targeting , 2010, Molecular membrane biology.

[224]  S. Svenson What nanomedicine in the clinic right now really forms nanoparticles? , 2014, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[225]  Sonke Svenson,et al.  Dendrimers as versatile platform in drug delivery applications. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[226]  G. Cevc,et al.  Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. , 1992, Biochimica et biophysica acta.

[227]  G. E. El Maghraby,et al.  Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. , 2000, International journal of pharmaceutics.

[228]  F. Yuan,et al.  Transvascular drug delivery in solid tumors. , 1998, Seminars in radiation oncology.

[229]  M. Blanco-Prieto,et al.  Lipid nanoparticles protect from edelfosine toxicity in vivo. , 2014, International journal of pharmaceutics.

[230]  Kazunori Kataoka,et al.  Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. , 2009, Advanced drug delivery reviews.

[231]  R. Duncan,et al.  Dendrimer-platinate: a novel approach to cancer chemotherapy. , 1999, Anti-cancer drugs.

[232]  George R. Newkome,et al.  Micelles. Part 1. Cascade molecules: a new approach to micelles. A [27]-arborol , 1985 .

[233]  Yang Yang,et al.  Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κB signal pathways , 2005, Molecular Cancer Therapeutics.

[234]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.